ABSTRA CT The development of a glucagon radioimmunoassay with a relatively high degree of specificity for pancreatic glucagon made possible studies of alpha cell function in healthy nondiabetic subjects and in patients with diabetes mellitus. In the former group mean fasting plasma glucagon averaged 108 ,uAg/ml (SEAI ±+10). In 12 juvenile-type diabetics fasting glucagon averaged 110 (±9) and in 33 adult-type diabetics the average was 114 (±8). The diabetic averages did not differ significantly from the nondiabetic subjects; however, when hyperglycemia was induced by glucose infusion in the nondiabetic subjects so as to simulate the fasting hyperglycemia of the diabetics, mean glucagon fell to 57 /Ag (±8), which was significantly below the diabetic mean.
In 28 healthy subjects the infusion of arginine elicited a rise in glucagon of at least 100 isg/ml with a peak level averaging 331 Ayg/ml (±22) at 40 min. This response to arginine was diminished but not abolished during hyperglycemia induced by simultaneous glucose infusion. In everyone of 45 diabetic subjects tested the infusion of arginine elicited a rise in glucagon of at least 140 pztg/ml to levels significantly greater than in nondiabetics. The peak glucagon level in juvenile-type diabetics averaged 458 ui*g/ml (SEM ±36) and in adulttype diabetics averaged 452 twg/ml (SEM +38). The glucagon response to arginine was unrelated to duration of diabetes, to body weight, type of diabetic treatment, or to other known factors. Marked hyperresponsiveness of glucagon to arginine infusion was observed in two patients with advanced Kimmelsteil-Wilson disease. Glucagon levels were markedly elevated in certain INTRODUCTION Despite the availability of relatively sensitive radioimmunoassays for glucagon for almost a decade (1) (2) (3) (4) , valid measurements of pancreatic glucagon in human plasma have only recently become possible (5) (6) (7) , and human alpha cell function has remained virtually unexplored. This is the consequence of technical problems which have plagued the radioimmunoassay, the most serious and intractable of which has been the problem of its specificity for pancreatic glucagon. It is now recognized that most antisera to pancreatic glucagon cross-react with so-called "glucagon-like immunoreactivity" (GLI), polypeptide substances in the upper gastrointestinal tract. Inasmuch as plasma GLI may comprise more than 90% of the total plasma "glucagon" measured with such antisera, it is extremely doubtful that earlier efforts to measure plasma levels of pancreatic glucagon in man (3, 8, 9) are quantitatively valid.
The chance discovery of a highly sensitive antiserum with an unprecedented degree of specificity for pan-pital patients without serious current acute illnesses. The latter group consisted of five patients convalescing from minor surgery who were considered to be in good general health at the time of testing. Although results of glucagon assays in the five patients were significantly lower than the remainder of the control group (P < 0.01), they were combined with the other controls and will be considered as a single group. Their ages ranged from 20 to 52 yr and averaged 26 yr. Their weights ranged from 56 to 87 kg and averaged 72 kg. None were regarded as obese.
The diabetic subjects in this study were Each experiment began with a 30 min baseline period, during which blood samples were obtained at 10-min intervals. L-Arginine monochloridel was infused in the antecubital vein as a 5%o glucose-free solution at a constant rate of 468 mg/kg body weight for 40 min. During the infusion period bloods were drawn at 5-min intervals for the first 10 min and at 10-min intervals thereafter. 8 ml of blood was drawn in a dry disposable plastic syringe. The blood was placed promptly in chilled tubes containing 12 mg of EDTA (Na2) and 4000 or 8000 U of Trasylol' in a volume of 0.8 ml. Blood specimens were immediately centrifuged at 40C and the plasma removed and frozen at -20C until the time of assay not more than 5 wk later.
Analytical methods. Insulin was measured by a modification (11) of the Yalow-Berson radioimmunoassay (12) .
Plasma glucose was measured by the Hoffman method (13) using the Technicon AutoAnalyzer. Glucagon was measured in duplicate by a modification (6) of the previously described radioimmunoassay (14) .
Antiserum obtained from rabbit G-58 was used for the measurement of all specimens. This antiserum cross-reacts very weakly with acid-alcohol extracts of gastrointestinal tissues; for example, a solution of jejunal extract, which reads 80 mug of glucagon-like immunoreactivity per ml using antiserum 78 J and 18 mrug/ml with antiserum G-128, the one used to obtain most of the physiologic data published 'R-Gene, Cutter Laboratories, Berkeley, Calif.
" Donated through the kindness of Dr. Frank G. Falco of Delbay Pharmaceuticals, Inc., Bloomfield, N. J. from this laboratory since 1963, reads only 2 mAg/ml with antiserum G-58 (10) . Furthermore, antiserum G-58 gives zero readings in plasma from dogs in which the glucagonsecreting portions of the pancreas have been resected, the first antiserum demonstrated to do so; in addition to greater specificity, i.e. diminished cross-reactivity with GLI, this antiserum is not influenced by gamma globulin or by other unidentified plasma factors which inhibit the reaction of glucagon-131I with certain antisera (15) . In the assay 0.1 ml of the G-58 antiserum (1: 9000) was added to 20 ,uAg of glucagon-'31I (specific activity 775-950 mCi/mg) in 0.1 ml volume, 500 U of Trasylol in 0.05 ml, and 0.05 ml of either the undiluted plasma sample or the crystalline glucagon beef-pork glucagon standard. All solutions were made up in 0.2 M glycine buffer containing 0.25% human albumin (Cutter Laboratories). The reaction mixture was incubated at 4°C for 4 days. Separation of free and bound glucagon-3I was carried out either by chromatography on Toyo paper using the previously described method (14) or by a modification (6) of the charcoal method of Herbert, Lau, Gottlieb, and Bleicher (11), which was found to give values identical with the paper method for unknown plasma samples. In a typical standard curve 50 ggg of crystalline glucagon causes a 9% fall in glucagon-'I bound to antibody. The standard deviation of the difference of each replicate from the mean of replicates-was +6.8,uAg/ml, so that a change of 40 Aug/ml or greater can be regarded as authentic with 95% confidence.
RESULTS

Nondiabetic subjects
Fasting glucagon levels. The mean fasting glucagon level of 28 healthy nondiabetic subjects was 108 ,uwg/ml .(SEM ±10). The range was from 50 to 210 Aqg/ml.
The plasma glucose concentration of this group averaged 87 mg/100 ml (SEM ±1). The glucagon concentration of the single female member of the normal group was 80 twg/ml. No correlation between glucose and glucagon concentration or between glucagon and insulin levels was observed.
To determine the degree of moment-to-moment change in glucagon concentration in the fasting state, in 25 of the nondiabetic subjects four blood samples were obtained within an hour and the standard deviation of the difference of these glucagon determinations from their mean was calculated. The value was ±13.2 ,uAg/ml, not far above the ±6.8 tttzg/ml standard deviation of the difference of replicates of a single blood specimen from their mean. This indicates a considerable degree of "within-hour" stability of plasma glucagon levels in normal fasting subjects.
The day-to-day variation in glucagon concentration was examined in a group of nine healthy males. The glucagon level averaged 126 ztg/ml on each of 2 consecutive days and the mean difference between the days was 15 Aag/ml with a maximum difference of 34 Atg/ml.
Effect of glucose infusion. Studies in dogs have
demonstrated that hyperglycemia profoundly suppresses pancreatic glucagon secretion ( 16, 17) . To determine if a similar effect occurs in man, 5% glucose was infused intravenously in eight healthy subjects at a constant rate of 1.5 g/min for 30 min, raising plasma glucose concentration progressively to a peak of 260 mg/100 ml (SEM +15) at the end of the infusion. The mean glucagon level declined from a pre-infusion level of 90 pAeg/ml (SEM ±8) to a nadir of 57 ,iug/ml (SEM +8). This value differed significantly from the preinfusion value (P < 0.01). The mean values are shown in Fig. 1 and in Table I .
Glucagon response to arginine infusion. Studies in dogs (18) and in man (9, 19) indicate that increased blood levels of some amino acids constitute a powerful stimulus to pancreatic glucagon secretion; although the results in humans were obtained with antisera which were not specific for pancreatic glucagon, they have been confirmed (6) with the more specific antiserum employed-here.
A total of 27 healthy males and one female have now been studied. The infusion of 468 mg/kg of arginine at a constant rate for 40 min was associated in every subject with a significant rise in plasma glucagon within the first 5 min of the infusion. The mean glucagon level rose from 108 wsg/ml (SEM ±10) to a peak of 331 ig/ml (SEM ±22) at 40 min, the time at which the infusion was discontinued. Mean glucagon concentration approached the baseline level within the next 30 min. The mean maximal rise was 239 iteg/ml (SEM +19). Every subject exhibited a maximal rise of at least 100 ittig/ml.
Insulin also rose promptly in all subjects from 8.5 JUU/ml (SEM +10) to a peak of 34 AU/ml (SEM ±4) at 30 and 40 min. The mean glucose level rose from 87 (SEM +1) to 99 mg/100 ml (SEM ±2). The mean results are depicted in Fig. 2 and in Table II .
Effect of induced hyperglycemia upon glucagon response to arginine. Hyperglycemia induced in dogs by glucose infusion suppresses completely the usually brisk hyperglucagonemic response to hyperaminoacidemia (18, 20) . To determine if arginine-induced hyperglucagonemia in man could be similarly suppressed, 10% glucose was infused intravenously at a rate of 15 ml/min in a group of seven healthy subjects. 30-40 min later, at which time plasma glucose averaged 286 mg/100 ml (SEM ±21) and glucagon 53 u~g/ml (SEM +4), arginine infusion was begun. The mean glucagon level rose to 190 isg/ml (SEM ±41) 20 min later, which is significantly less than the rise to 304 Ag/ml (SEM ±23) observed at 20 min in normoglycemic subjects. The mean values are shown in Fig. 3 and in Table III . It would appear that in normal subjects the glucagon rise in response to this dose of arginine is only slightly reduced by induced hyperglycemia, and that the levels attained are at all times less than in normoglycemic subjects. 
Diabetic subjects
Fasting glucagon levels. Among 12 patients classified as insulin dependent, ketoacidosis-prone, juveniletype diabetics the fasting glucagon averaged 118 Alyg/ml (SEM +9) with a range of 70-200 Aug/ml. The mean fasting plasma glucose level in this group was 198 mg/ 100 ml (SEM +25) with a range from 66 to 385 mg/ 100 ml.
Among 33 adult-type, insulin-independent diabetics the average was 114 /,wg/ml (SEM +8) and the range from 10 to 240 /Aig/ml. Glucose averaged 177 mg/100 ml (SEM ±10).
The mean fasting glucagon level of the diabetic groups did not differ significantly from that of nondiabetic subjects nor from each other (Fig. 4) IA,~g/ml (SEM ±19) and ranged from 40 to 240 ,ug/ml.
Three subjects were treated with diet alone; their fasting glucagon levels were 100, 180, and 90 ,tjtg/ml.
No relationship between the form of diabetic therapy and the fasting glucagon concentration was evident.
Relationship between glucose and glucagon concentration in diabetic and nondiabetic subjects
The lack of a significant difference in the fasting glucagon level of nondiabetic and diabetic subjects was unexpected in view of the fact that hyperglycemia, which effectively suppressed glucagon in the nondiabetic group, was present in the majority of the diabetics in this series. Since a "normal" glucagon level in the face of hyperglycemia might, in fact, represent a state of relative hyperglucagonemia, glucagon concentration of diabetics and nondiabetics with similar glucose levels were compared.
In Fig. 5 the glucagon values in diabetic and nondiabetic subjects are plotted as a function of glucose concentration. Seven of the diabetics had fasting glucose levels below 110 mg/100 ml because of aggressive therapy with insulin or oral antihyperglycemic agents; the mean glucagon level of the seven normoglycemic diabetics averaged 149 /Atg/ml (SEM ± 16), but did not differ significantly (0.05 < P < 0.1) from the 108 Alsg/ ml average of the 28 nondiabetics. Three of these seven diabetics were of the juvenile type (Fig. 5 A) .
The glucagon level of 19 diabetics with fasting hyperglycemia was compared with that of nine nondiabetics in whom hyperglycemia in excess tt/g/ml (SEM +10) with a range from 40 to 170 /Ag/ml.
These results are depicted in Fig. 5 infusing glucose at a and 50 min (P < 0.02). The mean maximal glucagon e e n ic rise in this group was 362 psg/ml (SEM ±33), signifiof the 30-mim glucose cantly greater (P < 0.01) than the 239 lqsg/ml (SEM 5fmg/100 ml and aver-±19) rise of the nondiabetic group.
). Mean minimal gluca-
The mean glucose level rose from 198 mg/100 ml 57 isyg/ml (SEM ±8). (SEM ±25) at the start of the infusion to 246 mg/100 '<0.001) than the 104 ml (SEM ±26) at 40 min and continued upward to a agon value of the dia-peak value of 271 mg/100 ml (SEM ±32) 30 min after vels were in the same termination of the infusion. This rise in glucose was re of the juvenile type; considerably greater than that of nondiabetics. Insulin 103 /Ai~g/ml (SEM ±6) could not be measured in this group because of insulin /ml; the 12 adult-type antibodies resulting from insulin treatment. The mean *n glucagon level of 105 results are depicted in Fig. 6 , and in Table IV . 
Glucagon response to arginine infusion in adult-type diabetics
The glucagon response to arginine infusion was tested in 33 adult-type diabetics. All 33 exhibited a prompt rise in plasma glucagon beginning within 10 min of the start of the infusion. Mean glucagon rose from 114 A'g/ ml (SEM ±8) at zero time to a peak of 452 Altg/ml (SEM ±38) at 30 min and returned gradually towards basal levels when the infusion was stopped. The glucagon levels were significantly greater than those of the nondiabetic group at 20 (P < 0.02), 30 (P < 0.01), and 40 min (P < 0.05). The mean of maximal increments was 371 (sEM ±36), significantly greater than 239
,.~g/ml (SEM +19) rise of nondiabetic subjects (P < 0.01). Mean glucose concentration rose from a preinfusion level of 177 mg/100 ml (SEM +10) to a peak value of 196 mg/100 ml (SEM ±11), not significantly greater than in normals. Insulin, which averaged 18 AU/ml (SEM +3) at the start of the infusion, rose to 66 AU/ml (SEM +12) at 40 min and then declined toward the baseline values upon termination of the infusion. A statistically significant relationship between the glucagon rise and either the glucose or the insulin increment was not observed.
The mean values are depicted in Fig. 7 and in Table  V . The maximal arginine-induced glucagon rise of nondiabetics, juvenile-type diabetics, and adult-type diabetics are compared in Fig. 8 .
Relationship of therapy to arginine-induced glucagon increment in adult-type diabetics
The nine adult-type diabetic patients receiving insulin therapy exhibited a mean maximal rise in plasma glucagon of 264 isg/ml (SEM ±40), while that of the 21 patients treated with a sulfonylurea was 381 twg/ml (SEM +35). The difference between these groups was not statistically significant (0.05 < P < 0.1). The three patients treated with diet alone rose 280, 430, and 1140 /A/Ag/ml, respectively.
Relationship of obesity to the fasting glucagon level and the maximal arginine-induced glucagon increment in adult-type diabetics
In contrast to the well-documented elevation in insulin levels observed in obesity (21) both in the fasting state and after stimulation of insulin secretion, which was again confirmed in these patients, glucagon levels appeared not to be influenced by obesity. No correlation between body weight and either the fasting glucagon level or the maximal glucagon increment during the infusion of arginine was observed. The mean fasting glucagon levels and the maximal arginine-induced glucagon increments of the 10 most obese of the adult-type diabetics, whose weight averaged 111 kg (90-135 kg) were compared with those of the 10 leanest of the group, whose weight averaged 59 kg (49-67 kg). The obese patients averaged in the fasting state 136 u/Ag/ml (SEM ±+13) and exhibited a mean maximal arginineinduced glucagon rise of 408 xsug/ml (SEM ±86), while in the lean group fasting glucagon levels and maximal arginine-induced glucagon rises averaged 102 ,Aug/ml (SEM +14) and 371 x4g/ml (SEM ±65), respectively. These values did not differ significantly. However, the fasting insulin level and the maximal insulin rise during arginine infusion were significantly greater in the obese group at the 2% and 5% level, respectively, and a significant correlation between body weight and fasting insulin (r = 0.58; P < 0.01) and arginine-induced insulin rise (r = 0.652; P < 0.01) was observed.
Relationship of the arginine-induced glucagon response of juvenile-type and adult-type diabetics to duration of diabetes In true ketoacidosis-prone, juvenile-type diabetes beta cells are presumed to be either absent or incapable of producing insulin in significant quantity. The brisk glucagon response to arginine exhibited by every juvenile type diabetic indicates that alpha cells retain their secretory function long after total loss of beta cell function. To determine if a gradual loss of alpha cell function occurs with time, the, relationship between the maximal glucagon rise of each juvenile-type diabetic and duration of diabetes was analyzed. A statistically significant relationship between glucagon response and duration of diabetes was not evident. Table VI shows the maximal arginine-induced glucagon increment and the duration of diabetes in all 12 juvenile-type diabetics. It is noteworthy that the patient with diabetes of 21 yr duration exhibited as brisk a rise in glucagon as the patient with diabetes of less than 1 yr duration. It must be concluded that diabetes of this type probably represents an isolated beta cell deficit without diffuse involvement of all cellular components of the islets of Langerhans.
Similar results were obtained in the 33 adult-type diabetics; a statistically significant correlation between maximal arginine-induced glucagon increment and the estimated duration of their diabetes was not observed.
Arginine-induced glucagon response in Kimmelsteil-Wilson disease
The striking reduction in insulin requirements observed to occur in many patients with advanced Kimmelsteil-Wilson disease has not been satisfactorily explained. Diminished glucagon secretion late in the course of diabetes seemed to be a possible mechanism worth considering. Two insulin-sensitive diabetic patients, in whom a reduction in insulin requirement had been attributed to Kimmelsteil-Wilson disease, received an arginine infusion test. In one glucagon rose from a 210 a/.Lg/ml fasting level to a peak of 650 A4g/ml at Glucagon levels in diabetic ketoacidosis Glucagon was measured in eight patients with relatively severe ketoacidosis. Their C02 was below 10 mEq/liter and their insulin requirements before their serum acetone had receded to "small" at 1: 1 dilution ranged from 425 to 850 U. Before treatment, glucagon averaged 587 Aig/ml (SEM ±+195), ranging from 230 to more than 2000 isAg/ml. With insulin treatment glucagon declined towards normal (Table VII) .
In four milder ketoacidotic patients, requiring 250 U of insulin or less during the first 6 hr of therapy (patients 8-12 in The study reveals that in normal human subjects intravenous administration of glucose suppresses glucagon secretion and that the infusion of arginine stimulates its secretion. Both of these effects, but particularly the effect of arginine, appear to be remarkably consistent in all subjects tested; a rise of at least 100 /qtg/ml has been observed during the infusion of 11.7 mg/kg per min of arginine in every one of 75 nondiabetic and dia-betic individuals studied thus far. The only exceptions have been patients with chronic pancreatitis reported elsewhere (6) (23) . However, the present study provides the first direct evidence of increased glucagon levels in patients with diabetes mellitus.
A state of relative hyperglucagonemia may be inferred from the fact that the mean fasting level of glucagon of both juvenile-type and adult-type diabetic groups does not differ significantly from that of the nondiabetic group, despite hyperglycemia which in nondiabetic subjects readily suppresses the glucagon level to subnormal values. It is reasonable to suppose that the inappropriately high glucagon, as well as the inappropriately low insulin levels, relative to the prevailing glucose level, are influencing the net hepatic glucose balance and increasing the severity of hyper glycemia, and the amount of insulin required to reduce hepatic glucose production to normal.
An unequivocal absolute increase in alpha cell function was demonstrated in diabetic subjects by means of the arginine infusion test. The mean glucagon level of diabetics rose within 10 min to a height which in nondiabetics was not attained before 40 min of infusion. The glucagon concentrations attained and the mean of maximal increments was significantly greater in both juvenile-type and adult-type diabetics than in nondiabetics. In 13 of the 33 patients with adult-type diabetes a rise to more than 500 /Agg/ml was observed; in two such patients glucagon rose to above 1000 Aqg/ml. In 5 of 12 juvenile-type diabetics plasma glucagon rose above 500 ptg/ml. Only one of 28 nondiabetics exhibited a rise above 500 Atg/ml.
Hyperresponsiveness of glucagon secretion to hyperaminoacidemia should increase hepatic glucose production and unfavorably influence blood glucose control unless a parallel release of insulin were to nullify this influence. This could explain the more marked hyperglycemic response to arginine noted in the juvenile-type diabetics, in whom no insulin release could have occurred, than in nondiabetics and adult-type diabetics, in whom a brisk rise in insulin accompanied the hyperglucogonemia. The hyperglycemic response to arginine averaged 12 mg/100 ml in the two latter groups, as compared to the 53 mg/100 ml in the juvenile-type diabetic group. Obviously, however, other factors are equally plausible as causes of hyperglycemia during the experimental period in juvenile-type diabetics.
The demonstration of an arginine-induced glucagon rise in patients with diabetes of long duration is noteworthy; in the juvenile-type diabetic group it indicates that alpha cells continue to function many years after beta cell function has been completely lost. This favors an isolated beta cell lesion in diabetes mellitus and speaks against a diffuse lesion involving all cellular components of the islets of Langerhans. The vigorous glucagon response to arginine observed in the two cases of Kimmelsteil-Wilson's disease suggests that even in the presence of extensive microangiopathic involvement of many tissues, the secretory function of the alpha cells is not diminished. Since hyalinization of the islets is said to occur in approximately 40% of diabetics (24) , the failure to encounter a single case of glucagon deficiency in the 45 diabetics studied is surprising.
The mechanism of the relative hyperglucagonemia encountered in diabetics in the fasting state However, in the absence of evidence that basement membrane thickening slows the transfer rate across capillaries this hypothesis is tenuous. A more attractive hypothesis, which can be supported in part with data already available, would ascribe diabetic hyposuppressibility of glucagon secretion by glucose to defective glucose penetration of alpha cells because of insulin lack. Hypoglycemia is well established as a stimulus to glucagon secretion, whether induced by insulin (26, 17) phlorizin (26) , or starvation (7). Hyperglycemia suppresses glucagon secretion (16, 17) when insulin is available, but seems not to suppress when insulin is lacking, as if glucose penetration of the alpha cell were insulin requiring. Preliminary studies in severely alloxan-diabetic dogs' and in the severely ketoacidotic patients reported here show remarkable elevations in plasma glucagon despite the extreme hyperglycemia; the administration of insulin reduces hyperglucagonemia and hyperglycemia simultaneously. However, the insulin lack hypothesis fails to explain the hyperglucagonemia of adult-type diabetics, in whom the insulin levels were greater than normal.
The demonstration of strikingly elevated plasma glucagon levels in certain patients with severe diabetic ketoacidosis may be of some clinical importance. Similar observations have been reported by Assan, Rosselin, and Derot (27) . The return of glucagon towards normal appears to coincide with the recession of the insulin resistance, which characterizes the early hours of therapy in severe ketoacidosis, and with the return towards normal of the glycemia and ketonemia. As stated before, high concentrations of a hormone, which accelerates the very processes in liver and, perhaps, fat tissue that insulin suppresses, may well contribute to the high insulin requirements and to the clinical configuration of the syndrome.
A final point concerns the report by Samols, Tyler and Mialhe, that tolbutamide suppresses glucagon secretion in human subjects and may exert its therapeutic effect, in part at least, through a reduction in glucagon secretion (28) . In the present study, however, the sulfonylurea-treated diabetics exhibited even more marked elevations in glucagon than the insulin-treated patients; while it is conceivable that their values represent a reduction from even higher levels prior to therapy, these data offer little support to this proposal.
It is concluded that (a) fasting glucagon levels of nondiabetic and diabetic subjects average slightly over 100 Alug/ml; (b) in nondiabetic subjects glucagon secretion is diminished by induced hyperglycemia to levels significantly below that of diabetics with comparable degrees of spontaneous hyperglycemia; (c) glucagon secretion is uniformly stimulated by arginine infusion in nondiabetic subjects, (d) in diabetic subjects without a history of pancreatitis the glucagon response to arginine is markedly exaggerated despite the hyperglycemia, and (e) in severe diabetic ketoacidosis glucagon levels may be extraordinarily high before treatment.
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